T2 Biosystems (NASDAQ:TTOO) research coverage has begun on StockNews.com
StockNews.com began to cover the shares of T2 Biosystems (NASDAQ: TTOO – Get a rating) in a note released Tuesday to investors. The company has placed a “hold” rating on the shares of the medical equipment supplier.
TTOO has been the subject of several other reports. Canaccord Genuity Group lowered its price target on T2 Biosystems from $3.00 to $1.50 and set a “buy” rating on the stock in a research report on Friday, February 18. Alliance Global Partners upgraded T2 Biosystems from a “neutral” rating to a “buy” rating and set a price target of $0.70 on the stock in a Friday, February 18 research report.
TTOO opened at $0.17 on Tuesday. The company has a 50-day moving average price of $0.32 and a 200-day moving average price of $0.41. The company has a market capitalization of $28.91 million, a P/E ratio of -0.51 and a beta of 0.53. T2 Biosystems has a 12-month low of $0.17 and a 12-month high of $1.44.
T2 Biosystems (NASDAQ: TTOO – Get a rating) last released its quarterly results on Thursday, May 5. The medical equipment supplier reported ($0.10) EPS for the quarter. The company had revenue of $7.23 million in the quarter. T2 Biosystems had a negative return on equity of 1,278.55% and a negative net margin of 194.37%.
Several institutional investors and hedge funds have recently changed their holdings of TTOO. Morgan Stanley increased its stake in shares of T2 Biosystems by 145.7% during the first quarter. Morgan Stanley now owns 171,988 shares of the medical equipment supplier valued at $278,000 after acquiring an additional 101,984 shares during the period. Barclays PLC increased its stake in T2 Biosystems by 277.5% in the third quarter. Barclays PLC now owns 29,359 shares of the medical equipment supplier valued at $27,000 after buying a further 21,581 shares in the last quarter. Geode Capital Management LLC increased its stake in T2 Biosystems by 1.6% in the third quarter. Geode Capital Management LLC now owns 1,516,085 shares of the medical equipment supplier valued at $1,387,000 after buying 23,473 additional shares in the last quarter. Natixis acquired a new stake in T2 Biosystems in the third quarter, valued at approximately $491,000. Finally, GSA Capital Partners LLP acquired a new stake in T2 Biosystems in the third quarter worth approximately $152,000. 11.23% of the shares are currently held by institutional investors and hedge funds.
T2 Biosystems Company Profile (Get a rating)
T2 Biosystems, Inc, an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. Its technology enables the detection of pathogens, biomarkers and other abnormalities in various types of unpurified patient samples, including whole blood, plasma, serum, saliva, sputum, cerebrospinal fluid and urine.
Get news and reviews for T2 Biosystems Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for T2 Biosystems and related companies with MarketBeat.com’s free daily email newsletter.